D-0513-2019 Class III Terminated
FDA drug recall D-0513-2019 was initiated by Lupin Pharmaceuticals Inc. on Feb 13, 2019 and is designated Class III. Reason for recall: CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results. The recall status is terminated (terminated Oct 6, 2020). Affected quantity: 44,640 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Feb 27, 2019
- Initiation Date
- Feb 13, 2019
- Termination Date
- Oct 6, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 44,640 bottles
Product description
Lovastatin Tablets USP, 40 mg, packaged in a) 60-count (NDC 68180-469-07 and b) 100-count (NDC 68180-469-01) bottles, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA.
Reason for recall
CGMP Deviations: Finished product made with lovastatin drug substance that was out of specification for individual impurity results.
Distribution pattern
Nationwide in the USA and Puerto Rico.
Code information
Lot #: a) G702755, Exp March 2020; b) G702756, Exp March 2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0513-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026